Wantstats
Company ProfilePremium

Ipsen Pharma

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Ipsen Pharma - Healthcare showcase

Year Founded & Workforce

1929

5,400 Employees

Industry

Healthcare

Services

Dysport
I

Ipsen Pharma Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ipsen Pharma Overview

Company Headquarters: Paris, France

Founded: 1929

Workforce: ~ 5,400+

Company Working:

Ipsen Pharma is a global pharmaceutical company operating in two segments, namely, specialty care and consumer healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rare disease areas. In the neuroscience segment, the company provides products for the treatment of cervical dystonia, adult spasticity, blepharospasm, hemifacial spasm, hyperhidrosis, and pediatric lower limb spasticity. Ipsen Pharma operates as a subsidiary of Mayroy S.A. The company has R&D centers and manufacturing sites located in China, France, Ireland, the UK, and the US. Ipsen Pharma is present in more than 115 countries and has a direct presence through corporates offices in around 35 countries across the globe.

Strategy

Ipsen Pharma is seeking to establish as a global biopharma company focused on innovation and specialty care that delivers differentiated therapeutics to meet unmet patient needs. Ipsen strategizes to look forward to innovative and sustainable growth in the near future. Additionally, the company concentrates on strategic collaboration and agreements for the expansion of its business.

Company Snapshot

$1,540M

Revenue

5,400

Employees

1929

Founded

Paris, France

Headquarters

SWOT Analysis

Strengths

  • Strong partnerships with key players
  • Robust research capabilities
  • Constitutes a large number of clinical trial candidates
  • Development and manufacturing of innovative drugs
  • High specialized research department
  • Focus on unmet needs of patients
  • With botulinum toxin type A Dysport, Ipsen offer a single product to treat a range of therapeutic indications
  • Well-developed R&D to boost manufacturing of a new generation of recombinant neurotoxins
  • Company has its direct commercial presence in over 30 countries worldwide which strengthens its market position

Weaknesses

  • Limited focus on Asian countries
  • Limited presence in the global market
  • Highly dependent on one market for revenue generation
  • Low presence in emerging markets can affect overseas trade
  • Overdependency on the European market for revenue generation appears to have adverse longer-term consequences for economic growth and development

Opportunities

  • Customer engagement campaigns
  • Collaborations with international partners
  • Strong product pipeline
  • Engaging in mergers and acquisitions
  • Strategic collaborations with other pharmaceutical companies, physicians and dermatologists to boost R&D
  • Building a pipeline of innovative products in botulinum toxin industry to gain maximum market share

Threats

  • High level of competition by strong players in the market
  • Highly competitive market
  • Stringent government policies
  • Fluctuations in demand hampers quality of product
  • High competition in the botulinum toxin market from other players can affect the company’s market share
  • Risks related to Intellectual Property Rights which could have a material impact on company’s business

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–PartnershipIpsen Pharma and Galderma entered into an exclusive partnership, wherein Galderma acquired the exclusive rights to develop, promote, and distribute Dysport for aesthetic indications in the Asia-Pacific countries.
September 2019Product ApprovalIpsen Pharma received FDA approval for Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients of age group 2 to 17. This approval is expected to boost the sales of botulinum toxin.

Product Offering

  • Ipsen Pharma
    • Dysport

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 1,540 Mn in 2015 to USD 2,067 Mn in 2017.
Ipsen Pharma — By Business Segment
Series (USD Mn)201520162017
Sales1,5401,6852,067
R&D Expenses204.8222.4287.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →